TriSalus Life Sciences, Inc. - Common Stock (TLSI)

TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reiterated its full-year 2026 revenue outlook of $54 million to $57 million, represe

TriSalus (TLSI) Q1 2026 Earnings Transcript

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device. President and Chief Executive Officer M

TriSalus (TLSI) Q4 2025 Earnings Call Transcript

TriSalus Q3 2025 results show strong 57% revenue growth but a wider-than-expected EPS loss. The company reaffirmed its 50% full-year growth outlook.

TriSalus (TLSI) Q3 2025 Earnings Call Transcript

TriSalus Life Sciences reports strong Q2 2025 revenue growth of 52% YoY to $11.2M, beating estimates. Losses narrow as commercialization of TriNav and PEDD platform gains momentum.

The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024.

Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025.